Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) — Stella

Home/Primary Hypercholesterolemia or Mixed Dyslipidemia/

View on ClinicalTrials.gov

Recruiting

Back to Primary Hypercholesterolemia or Mixed Dyslipidemia trials

Trial locations(4 sites)

South Korea

Novartis Investigative Site, Yangsan, Gyeongsangnam-do

Novartis Investigative Site, Busan

Novartis Investigative Site, Seoul

Novartis Investigative Site, Taegu

Key details

Sponsor

Novartis Pharmaceuticals

Enrollment target

~1,500 participants

Started

August 2025

Primary completion

January 2031

Age range

18 Years – 100 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.